Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
|Videos|July 3, 2020
Are Pregnant Women at Worse Coronavirus Risk?
Author(s)Kevin Kunzmann
A discussion with a Yale expert on what new CDC data shows.
Advertisement
New data from the US Centers for Disease Control and Prevention (CDC) assessing 8200-plus pregnant women in the US since March showed that pregnant women have been statistically at greater risk of severe
The findings also showed pregnancy was associated with greater risk of hospitalization, ICU admission, and even mechanical ventilator care than for women who were not pregnant.
What was also uncovered is that, among those pregnant and with laboratory-confirmed infection, most severely ill women were minorities—as has been the case for general coronavirus cases in the US overall.
In some ways, these findings, and those that may proceed them, may inform the timeline by which women who are freely able to decide when they childbear, actually do so. Could we have a post-pandemic baby boom? Potentially, so said a recent expert.
In an interview with Contagion, Mary Jane Minkin, MD, OB/GYN and clinical professor at Yale University, discussed the new CDC findings and how they impact pregnancy health care.
Minkin also discussed the ever-evolving nature of pregnancy health understanding in the era of COVID-19, how mental health is an even more integral facet of care for this patient population right now, and how US pregnancies may be influenced by what we’re currently learning.
Advertisement
Related to this article
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Advertisement
Advertisement